cis-4-Hydroxy-L-proline-d3

CAT:
804-HY-40136S
Size:
1 mg
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
cis-4-Hydroxy-L-proline-d3 - image 1

cis-4-Hydroxy-L-proline-d3

  • UNSPSC Description:

    cis-4-Hydroxy-L-proline-d3 is the deuterium labeled cis-4-Hydroxy-L-proline. cis-4-Hydroxy-L-proline, a proline analogue, is an inhibitor of collagen production. cis-4-Hydroxy-L-proline could inhibit fibroblast growth by preventing the deposition of triple-helical collagen on the cell layer. cis-4-Hydroxy-L-proline also depresses the growth of primary N-nitrosomethylurea-induced rat mammary tumors[1][2][3][4].
  • Target Antigen:

    Endogenous Metabolite; Isotope-Labeled Compounds
  • Type:

    Isotope-Labeled Compounds
  • Related Pathways:

    Metabolic Enzyme/Protease;Others
  • Applications:

    Metabolism-protein/nucleotide metabolism
  • Field of Research:

    Cancer
  • Purity:

    99.0
  • Solubility:

    H2O : 100 mg/mL (ultrasonic;warming)
  • Smiles:

    O=C(O)[C@]1([2H])C[C@H](O)C([2H])([2H])N1
  • Molecular Weight:

    134.15
  • References & Citations:

    [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.|[2]Kao WW, et, al. Proline analogue removes fibroblasts from cultured mixed cell populations. Nature. 1977 Mar 3;266(5597):63-4.|[3]Lewko WM, et, al. Sensitivity of N-nitrosomethylurea-induced rat mammary tumors to cis-hydroxyproline, an inhibitor of collagen production. Cancer Res. 1981 Jul;41(7):2855-62.|[4]Riley DJ, et, al. Prevention of bleomycin-induced pulmonary fibrosis in the hamster by cis-4-hydroxy-l-proline. Am Rev Respir Dis. 1981 Apr;123(4 Pt 1):388-93.|[5]Tan EM, et, al. Proline analogues inhibit human skin fibroblast growth and collagen production in culture. J Invest Dermatol. 1983 Apr;80(4):261-7.
  • Shipping Conditions:

    Room Temperature
  • Storage Conditions:

    -20°C, 3 years; 4°C, 2 years (Powder)
  • Clinical Information:

    No Development Reported